التفاصيل البيبلوغرافية
| العنوان: |
Triptolide Analogs for the Treatment of Autoimmune and Inflammatory Disorders |
| Document Number: |
20090234000 |
| تاريخ النشر: |
September 17, 2009 |
| Appl. No: |
12/474305 |
| Application Filed: |
May 29, 2009 |
| مستخلص: |
The present invention provides synthetic methods and compositions for treatment of autoimmune and anti-inflammatory disorders comprising administering an effective amount of a derivative of triptolide alone or in combination or alternation with other anti-autoimmune or anti-inflammatory compounds. |
| Inventors: |
Wang, Susheng (Clarkston, GA, US); Liotta, Dennis C. (Atlanta, GA, US); Snyder, James P. (Atlanta, GA, US); Venkatesan, Hariharan (San Diego, CA, US) |
| Claim: |
1-22. (canceled) |
| Claim: |
23. A compound of the formula (II), (IV) or (III): [chemical expression included] or its pharmaceutically acceptable salt or prodrug thereof, wherein: (a) the dotted line indicates the presence of either a single or double bond, wherein the valences of a single bond are completed by hydrogens; (b) A, B, D and E are O; and R1, R2, R3, R4, R5 and R6 are independently hydrogen, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, alkaryl, arylalkyl. |
| Claim: |
24. The compound of claim 23, wherein the compound has the formula (II). |
| Claim: |
25. The compound of claim 23, wherein the compound has the formula (IV). |
| Claim: |
26. The compound of claim 23, wherein the compound has the Formula (III). |
| Claim: |
27. The compound of claim 23, wherein the compound has the formula (II); and R1 is t-butyl, isopentyl, neopentyl, isohexyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, cycloalkyl, aryl, alkylaryl or arylalkyl. |
| Claim: |
28. The compound of claim 23, wherein the compound has the formula (IV); and R1 is t-butyl, isopentyl, neopentyl, isohexyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, cycloalkyl, aryl, alkylaryl or arylalkyl. |
| Claim: |
29. The compound of claim 23, wherein the compound has the formula (III); and R1 is t-butyl, isopentyl, neopentyl, isohexyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, cycloalkyl, aryl, alkylaryl or arylalkyl. |
| Claim: |
30. The compound of claim 23 wherein R5 and R6 are independently hydrogen, or alkyl. |
| Claim: |
31. The compound of claim 23 wherein R2 is hydrogen or alkyl. |
| Claim: |
32. The compound of claim 23 wherein R1 and R4 are independently alkyl, alkenyl or alkynyl. |
| Claim: |
33. The compound of claim 23 wherein alkyl is substituted with hydroxyl, alkoxy, carboxyl, acyl, acyloxy, amino, amido, alkylamino, dialkylamino, thiol, sulfonyl, sulfate or phosphate. |
| Claim: |
34. The compound of claim 23, wherein alkyl is substituted with hydroxyl or amino. |
| Claim: |
35. The compound of claim 23 wherein: R1, R2, R3 and R4 are independently hydrogen or alkyl; and R5 and R6 are hydrogen. |
| Claim: |
36. The compound of claim 35, wherein R2 and R3 are hydrogen. |
| Claim: |
37. The compound of claim 35, wherein R2 is alkyl and R3 is hydrogen. |
| Claim: |
38. The compound of claim 35, wherein R1 and R4 are alkyl; and R2 and R3 are hydrogen. |
| Claim: |
39. The compound of claim 35, wherein R1, R2 and R4 are alkyl; and R3 is hydrogen. |
| Claim: |
40. The compound of claim 35, wherein R1 t-butyl; R4 is methyl; and R2 and R3 are hydrogen or methyl. |
| Claim: |
41. A pharmaceutical composition comprising the compound of claim 23 in combination with a pharmaceutically acceptable carrier. |
| Claim: |
42. The pharmaceutical composition of claim 41 in combination with another active agent. |
| Current U.S. Class: |
514/475 |
| Current International Class: |
61; 07 |
| رقم الانضمام: |
edspap.20090234000 |
| قاعدة البيانات: |
USPTO Patent Applications |